Welcome to the e-CCO Library!

P482: Transanal minimally invasive proctectomy (TaMIP) in patients with inflammatory bowel diseases (IBD) within the TaTME international database
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, A. Spinelli6,7, R. Hompes4, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative

Created: Thursday, 21 February 2019, 9:14 AM
P483 Vedolizumab serum drug levels are not associated with clinical outcomes or markers of disease activity in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Shields1, J.P. Seenan1, E. Nowell1, A. Dunlop2, P. Galloway2, J. Macdonald1

Created: Thursday, 30 January 2020, 10:12 AM
P483: Differences in biologic therapy utilisation amongst early and late-onset inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Raimundo Fernandes*, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa

Created: Friday, 22 February 2019, 9:49 AM
P483: Factors affecting the efficacy of granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A multi-centre retrospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Yamamoto1, T. Iida2, K. Ikeya2, M. Kato2, A. Matsuura2, S. Tamura3, R. Takano3, S. Tani4, S. Osawa4, K. Sugimoto3, T. Shimoyama*1, H. Hanai2

Created: Friday, 22 February 2019, 9:41 AM
P483: Golimumab response in Ulcerative Colitis as early as week 2: What can we take from this?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kumar, L.(1)*;O'Morain, N.(1);Sheridan, J.(1);Coe, C.(1);Egan, C.(1);Jones, F.(1);Cullen, G.(1);Doran, P.(2);Leyden, J.(3);Galligan, M.(2);McCarthy, J.(4);O'Toole, A.(5);Kevans, D.(6);Egan, L.(7);Doherty, G.(1);
Created: Friday, 14 July 2023, 11:05 AM
P483: Infliximab but not adalimumab drug levels predict faecal calprotectin response in Inflammatory Bowel Disease patients on dose-intensified anti-TNF therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Noack, S.(1);Little, R.(1);Vaz, K.(1);Ward, M.(1);Sparrow, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P483: Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

K.K. Jørgensen1*, G.L. Goll2, J. Sexton2, I.C. Olsen2,3, N. Bolstad4, K.E. Lundin5,6, I.P. Berset7, E.A. Haavardsholm2,6, C. Mørk8, T.K. Kvien2,6, J. Jahnsen1,6

Created: Thursday, 21 February 2019, 9:14 AM
P483: Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar
Year: 2022
Source: ECCO'22
Authors: Ritter, T.E.(1);Mehta, S.A.(2);Van Anglen, L.J.(2);
Created: Friday, 11 February 2022, 3:56 PM
P483: Relapse after discontinuation of the maintenance drug in patients with Ulcerative proctosigmoiditis: preliminary result of a prospective randomized trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choi H.*1, Gweon T.-G.2, Lee B.-I.2, Lee K.-M.2, Kim S.-W.2, Kang S.-B.2, Ji J.-S.2, Han S.-W.2, Choi M.-G.2

Created: Wednesday, 20 February 2019, 10:36 AM
P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Mohammad1, A. Alshahrani1,2, Y. Bao1, R. Alramdan1, A. Rajani1, U. Chauhan1, B. Salena1, F. Tse1, E. Greenwald1, S. Albashir1, S. Halder1, D. Armstrong1, J. Marshall1, N. Narula1

Created: Thursday, 30 January 2020, 10:12 AM
P484: Access to biologics and biosimilars across 11 European Union countries
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Lakatos*1, E. Domenech2, H. Kellner3, J. Marsal4, H. Fowler5, C. Agboton5, N. Georgitseas6, M. Cassese7, S. Anwar6, A. Venugopal7, P. Audhya5

Created: Friday, 22 February 2019, 9:49 AM
P484: Dietary therapy using the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sigall Boneh R.*1, Sarbagili Shabat C.1, Boaz M.2,3, Levine A.1,4, Chermesh I.5, Ben Avraham S.1, Cohen Dolev N.1

Created: Wednesday, 20 February 2019, 10:36 AM
P484: Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
Year: 2022
Source: ECCO'22
Authors: Levartovsky, A.(1);Cohen, I.(1);Abitbol, C.M.(1);Yavzori, M.(1);Fudim, E.(1);Picard, O.(1);Kopylov, U.(1);Ben-Horin, S.(1);Ungar, B.(1);
Created: Friday, 11 February 2022, 3:56 PM
P484: Hepatitis B vaccination in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Cortez Pinto*1, J. Castela1, J. Moleiro1, J. Pereira da Silva1, I. Rosa1, A. Dias Pereira1

Created: Friday, 22 February 2019, 9:41 AM
P484: Inflammatory Bowel Disease exercise and diet habits (IBDeat) study: chronic metabolic disease risk factors among IBD patients in New Zealand
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yap, J.(1)*;Wall, C.(2);Meredith-Jones, K.(1);Iosua, E.(1);Osborne, H.(1);Schultz, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P484: Infliximab and vedolizumab show a different effect on clot formation in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Detrez1*, V. Ballet2, M. Peeters1, G. Van Assche2, S. Vermeire2, M. Ferrante2, A. Gils1

Created: Thursday, 21 February 2019, 9:14 AM
P484: Remote monitoring allows an individualized approach and showed excellent usability at the infusion unit
Year: 2021
Source: ECCO'21 Virtual
Authors: Fierens, L.(1);Geens, P.(2);De Dycker, E.(2);Paps, A.(2);Lambrechts, T.(2);Sabino, J.(1,2);Vermeire, S.(1,2);Ferrante, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P485 Switching infliximab biosimilar: No adverse impact on inflammatory bowel disease control or drug levels with the first or second switch
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Luber1, R. O’Neill2, S. Singh2, Z. Arkir3, P. Irving1

Created: Thursday, 30 January 2020, 10:12 AM
P485: An Assessment Of A Guided Self-Help and Patient Initiated Review Pathway for Ulcerative Proctitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Saunders, J.(1)*;Maroo, S.(1);Brownson, E.(1);Boulton Jones, R.(1);
Created: Friday, 14 July 2023, 11:05 AM